Originally published as JCO Early Release 10.1200/JCO.2006.06.1101 on September 11 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bepler, G. Articles by Simon, G. Search for Related Content PubMed PubMed Citation Articles by Bepler, G. Articles by Simon, G. Social Bookmarking                            What's this?

RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer

Gerold Bepler, Irina Kusmartseva, Swati Sharma, Ashish Gautam, Alan Cantor, Anupama Sharma, George Simon

From the Program and Division of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Address reprint requests to Gerold Bepler, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute, MRC-4W, Room 4046, 12902 Magnolia Dr, Tampa, FL 33612-9497; e-mail: beplerg{at}moffitt.usf.edu

PURPOSE: RRM1 encodes the regulatory subunit of ribonucleotide reductase and is a molecular target of gemcitabine. Previous studies showed increased RRM1 expression on continuous exposure of cell lines to gemcitabine and suggested improved survival for patients with low as opposed to high tumoral RRM1 expression when treated with gemcitabine-containing chemotherapy. However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed.

PATIENTS AND METHODS: We constructed genetically modified lung cancer cell lines with increased and decreased RRM1 expression to investigate the in vitro 50% inhibitory concentration (IC₅₀) for gemcitabine, cisplatin, and carboplatin. A prospective phase II clinical trial in patients with locally advanced non–small-cell lung cancer was conducted with pretreatment tumor collection for determination of RRM1 and ERCC1 expression by real-time reverse transcriptase polymerase chain reaction. The levels of gene expression were correlated with tumor response after two cycles of gemcitabine and carboplatin.

RESULTS: In cell lines with a genetically engineered 15-fold RRM1 expression range, the gemcitabine IC₅₀ had a 100-fold range, and the cisplatin and carboplatin IC₅₀ had a two-fold range. They were highest in constructs with high RRM1 expression. In the prospective clinical trial, RRM1 expression was significantly (P = .002) and inversely correlated (r = –0.498) with disease response. ERCC1 expression showed a similar trend (P = .099).

CONCLUSION: The results strongly suggest that tumoral RRM1 expression is a major predictor of disease response to gemcitabine/platinum chemotherapy. ERCC1 expression is predictive of response albeit to a lesser degree.

published online ahead of print at www.jco.org on September 11, 2006.

Supported by Grants No. R01 CA102726 and R21 CA106616 from the National Cancer Institute.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Chhatwani, E. Cabebe, and H. A. Wakelee Adjuvant Treatment of Resected Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 194 - 200. [Abstract] [Full Text] [PDF]

				S. Saviozzi, P. Ceppi, S. Novello, P. Ghio, M. Lo Iacono, P. Borasio, A. Cambieri, M. Volante, M. Papotti, R. A. Calogero, et al. Non-Small Cell Lung Cancer Exhibits Transcript Overexpression of Genes Associated with Homologous Recombination and DNA Replication Pathways Cancer Res., April 15, 2009; 69(8): 3390 - 3396. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti, P. Ceppi, S. Novello, and M. Papotti Chemotherapy Treatment Decisions in Advanced Non-small Cell Lung Cancer Based on Histology ASCO Educational Book, January 1, 2009; 2009(1): 431 - 435. [Abstract] [Full Text] [PDF]

				R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, A. Olsen, N. Curtin, A. Boddy, P. McHugh, D. Newell, et al. Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7917 - 7923. [Abstract] [Full Text] [PDF]

				B. Besse and T. Le Chevalier Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect? J. Clin. Oncol., November 1, 2008; 26(31): 5014 - 5017. [Full Text] [PDF]

				S.-O. Kim, J.-Y. Jeong, M.-R. Kim, H.-J. Cho, J.-Y. Ju, Y.-S. Kwon, I.-J. Oh, K.-S. Kim, Y.-I. Kim, S.-C. Lim, et al. Efficacy of Gemcitabine in Patients with Non-Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene Clin. Cancer Res., May 15, 2008; 14(10): 3083 - 3088. [Abstract] [Full Text] [PDF]

				D. Breen and F. Barlesi The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 805 - 811. [Abstract] [Full Text] [PDF]

				G. Bepler Genes Predictive of Chemotherapeutic Efficacy in Non-small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 350 - 352. [Abstract] [Full Text] [PDF]

				J.-C. Soria ERCC1-Tailored Chemotherapy in Lung Cancer: The First Prospective Randomized Trial J. Clin. Oncol., July 1, 2007; 25(19): 2648 - 2649. [Full Text] [PDF]

				G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al. Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746. [Abstract] [Full Text] [PDF]

				M. Cobo, D. Isla, B. Massuti, A. Montes, J. M. Sanchez, M. Provencio, N. Vinolas, L. Paz-Ares, G. Lopez-Vivanco, M. A. Munoz, et al. Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2747 - 2754. [Abstract] [Full Text] [PDF]

				Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer N. Engl. J. Med., February 22, 2007; 356(8): 800 - 808. [Abstract] [Full Text] [PDF]